; Juniper Pharmaceuticals | Investor Relations Overview

Investor Relations Overview

Corporate Profile

Juniper Pharmaceuticals (Nasdaq: JNP) is focused on developing therapeutics that address unmet medical needs in women’s health.  We are advancing a product pipeline leveraging proprietary  drug delivery technologies for targeted, intravaginal drug delivery.  We expect this delivery approach can provide effective singular and combination treatment options with local delivery to target organs, reduced side effects, and improved compliance -- all to better meet patient needs.

Crinone

CRINONE® (progesterone gel) is Juniper’s most successful product developed to date and our single largest revenue source. Commercially available in over 90 countries around the world, Crinone is marketed by Merck KGaA, Darmstadt, Germany, outside the U.S. and by Allergan, Inc. in the U.S.  More >>

Stock Quote

JNP (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Price$5.60
Change (%) Stock is Down 0.11 (1.93%)
Volume27,297
Data as of 09/29/16 4:00 p.m. ET
Minimum 20 minute delayRefresh quote
Recent NewsMore >>
DateTitle 
08/31/16Juniper Pharmaceuticals to Present at Rodman & Renshaw Global Investment Conference on September 12, 2016Printer Friendly Version
08/17/16Juniper Pharmaceuticals Reports Results from Phase 2b Clinical Trial of COL-1077 Lidocaine Vaginal Gel in Gynecologic Procedure PainPrinter Friendly Version
08/04/16Juniper Pharmaceuticals Reports Second Quarter 2016 Financial ResultsPrinter Friendly Version
07/26/16Juniper Pharmaceuticals to Report Second Quarter 2016 Results on August 4, 2016Printer Friendly Version